← Back to Clinical Trials
Recruiting NCT06323629

NCT06323629 Effects of Recursive Self-feedback on Speech Production in Aphasia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06323629
Status Recruiting
Phase
Sponsor University of South Florida
Condition Aphasia
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2024-08-29
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Adaptive recursive self-feedback procedureNon-adaptive recursive self-feedback procedure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2024-08-29 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to test the effects of recursive self-feedback procedures on spontaneous speech production in stroke survivors with impaired speech production (aphasia). The main question it aims to answer is: • To what extent can stroke survivors with aphasia use their self-feedback alone to improve their spontaneous speech production? Participants will be engaged in the following activities: * They will perform language and cognitive tasks. * Afterwards, they will receive treatments using tablets and headphones at no cost to them. * The experimental treatments (recursive self-feedback procedures) entails responding to prompts, listening to playbacks of their speech response and attempt to minimize/correct the errors in the next attempt. This process will be repeated multiple times per prompt. * The experimental treatments are two: an adaptive version that adapts the complexity of the treatment prompt and a non-adaptive version that does not adapt task complexity. * Researchers will compare the experimental treatments to see if both have similar effects on improving spontaneous speech production.

Eligibility Criteria

Inclusion Criteria: * 6 months post left hemisphere stroke * Aphasia due to left hemisphere stroke * Dominant English speaker Exclusion Criteria: * Speech-language deficits due to neurological insults such as Parkinson's disease, neurodegenerative conditions etc. * Uncorrected sensory impairments. * Language comprehension impairment. * Severe cognitive impairment.

Contact & Investigator

Central Contact

Gerald C. Imaezue, PhD

✉ gimaezue@usf.com

📞 (813)974-2464

Principal Investigator

Gerald C. Imaezue, PhD

PRINCIPAL INVESTIGATOR

University of South Florida

Frequently Asked Questions

Who can join the NCT06323629 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06323629 currently recruiting?

Yes, NCT06323629 is actively recruiting participants. Contact the research team at gimaezue@usf.com for enrollment information.

Where is the NCT06323629 trial being conducted?

This trial is being conducted at Tampa, United States.

Who is sponsoring the NCT06323629 clinical trial?

NCT06323629 is sponsored by University of South Florida. The principal investigator is Gerald C. Imaezue, PhD at University of South Florida. The trial plans to enroll 45 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology